1. Product safety warnings ironically increase sales over time

   Clinical study 19 October 2013 Pages: 1 - 1

2. Recommendations adopted at PRAC's September meeting

   News item 19 October 2013 Pages: 2 - 2

3. FDA investigates incidence of vascular AEs in ponatinib trial

   News item 19 October 2013 Pages: 2 - 2

4. Post-approval safety issues not related to level of drug innovation

   Incidence study 19 October 2013 Pages: 3 - 3

5. Gliptins provide safe, effective option for elderly diabetics

   Clinical study 19 October 2013 Pages: 3 - 3

6. One in seven patients discontinue ticagrelor in real world

   Epidemiology clinical study 19 October 2013 Pages: 3 - 3

7. Antidepressants may lead to higher risk of diabetes mellitus

   Review 19 October 2013 Pages: 4 - 4

8. Distinct safety profiles of thalidomide and lenalidomide

   Epidemiology population study 19 October 2013 Pages: 4 - 4

9. Complex findings from long-term HRT studies

   Clinical study 19 October 2013 Pages: 4 - 4

10. Acetazolamide

    Case report 19 October 2013 Pages: 5 - 5

11. Adalimumab

    Case report 19 October 2013 Pages: 5 - 5

12. Adalimumab

    Case report 19 October 2013 Pages: 5 - 5

13. Adalimumab/efalizumab/etanercept

    Case report 19 October 2013 Pages: 5 - 5

14. Amfetamine mixed salts

    Case report 19 October 2013 Pages: 6 - 6

15. Adenosine triphosphate

    Case report 19 October 2013 Pages: 6 - 6

16. Alternative medicine

    Case report 19 October 2013 Pages: 6 - 6

17. Albendazole

    Case report 19 October 2013 Pages: 6 - 6

18. Amfetamine/tramadol

    Case report 19 October 2013 Pages: 7 - 7

19. Amphotericin B liposomal

    Case report 19 October 2013 Pages: 7 - 7

20. Amiodarone

    Case report 19 October 2013 Pages: 7 - 7

21. Amoxicillin/clavulanic acid

    Case report 19 October 2013 Pages: 7 - 7

22. Antineoplastics

    Case report 19 October 2013 Pages: 8 - 8

23. Antiretrovirals

    Case report 19 October 2013 Pages: 8 - 8

24. Antibacterials

    Case report 19 October 2013 Pages: 8 - 8

25. Antineoplastics

    Case report 19 October 2013 Pages: 8 - 8

26. Barbiturates/muscle relaxants/potassium chloride

    Case report 19 October 2013 Pages: 9 - 9

27. Azathioprine/interferon-β-1a

    Case report 19 October 2013 Pages: 9 - 9

28. Azathioprine

    Case report 19 October 2013 Pages: 9 - 9

29. Baclofen

    Case report 19 October 2013 Pages: 9 - 9

30. Bupropion

    Case report 19 October 2013 Pages: 10 - 10

31. Calcium polystyrene sulfonate

    Case report 19 October 2013 Pages: 10 - 10

32. Botulinum toxin A

    Case report 19 October 2013 Pages: 10 - 10

33. Calcium carbonate

    Case report 19 October 2013 Pages: 10 - 10

34. Cefepime/vancomycin

    Case report 19 October 2013 Pages: 11 - 11

35. Capecitabine

    Case report 19 October 2013 Pages: 11 - 11

36. Carbamazepine

    Case report 19 October 2013 Pages: 11 - 11

37. Carboplatin

    Case report 19 October 2013 Pages: 11 - 11

38. Chlorpromazine/clomipramine/risperidone interaction

    Case report 19 October 2013 Pages: 12 - 12

39. Ceftriaxone

    Case report 19 October 2013 Pages: 12 - 12

40. Ceftriaxone

    Case report 19 October 2013 Pages: 12 - 12

41. Ceftriaxone

    Case report 19 October 2013 Pages: 12 - 12

42. Cisatracurium besilate

    Case report 19 October 2013 Pages: 13 - 13

43. Ciclosporin/mycophenolate mofetil

    Case report 19 October 2013 Pages: 13 - 13

44. Cisatracurium besilate

    Case report 19 October 2013 Pages: 13 - 13

45. Citalopram/clonazepam/olanzapine overdose

    Case report 19 October 2013 Pages: 14 - 14

46. Cisplatin/docetaxel

    Case report 19 October 2013 Pages: 14 - 14

47. Citalopram/lamotrigine

    Case report 19 October 2013 Pages: 14 - 14

48. Cisplatin

    Case report 19 October 2013 Pages: 14 - 14

49. Clomipramine

    Case report 19 October 2013 Pages: 15 - 15

50. Clonazepam/phenytoin

    Case report 19 October 2013 Pages: 15 - 15